The National Institutes of Health's Alzheimer's Disease Prevention Initiative was organized to investigate pharmacological interventions and to identify factors that will assist in early recognition of AD and delay the devel opment of AD. A collaborative association with federal and private agencies has allowed for diverse investigations that include biologic and epidemiologic research; instrument development to identify high-risk individuals, facilitating clinical trials; and researching alternate strategies to treat behavioral disturbances in AD patients.
New drugs to reduce symptoms of AD are being studied in clinical trials. Other research is being done to identify factors related to patients' and care-givers' coping and stress as well as support mechanisms in dealing with progressive nature of AD.
Was this article helpful?